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Dengue fever (DF) has become common in western travel-
ers to the tropics. To improve the basis for travel advice, risk fac-
tors and dengue manifestations were assessed in 107 Swedish
patients for whom DF was diagnosed after return from travel in
1998 and 1999. Patient data were compared with data on a
sample of all Swedish travelers to dengue-endemic countries in
the same years. Only three of the patients had received pretrav-
el advice concerning DF from their physicians. Hemorrhagic
manifestations were common (21 of 74 patients) but caused no
deaths. Risk factors for a DF diagnosis were travel to the Malay
Peninsula (odds ratio [OR] 4.95; confidence interval [CI] 2.92 to
8.46), age 15–29 years (OR 3.03; CI 1.87 to 4.92), and travel
duration >25 days (OR 8.75; CI 4.79 to 16.06). Pretravel advice
should be given to all travelers to DF-endemic areas, but young
persons traveling to southern and Southeast Asia for >3 weeks
(who constituted 31% of the patients in our study) may be more
likely to benefit by adhering to it. 
D
engue fever (DF) is an acute, self-limiting febrile viral dis-
ease of 2–7 days’ duration, characterized by a sudden
onset of fever and a variety of other symptoms such as severe
headache, joint and muscular pain, retroorbital pain, and rash.
Occasionally, hemorrhagic manifestations, such as skin hemor-
rhages, gum bleeding, epistaxis, menorrhagia, and gastroin-
testinal hemorrhage, occur. Dengue hemorrhagic fever (DHF)
is a more severe disease with fever, hemorrhagic phenomena,
thrombocytopenia, and plasma leakage caused by increased
vascular permeability. In patients with DHF, a sometimes-fatal
circulatory failure with hypovolemic shock, called dengue
shock syndrome, can develop (1,2).
The dengue virus (formal name: Dengue virus [DENV])
belongs to the family Flaviviridae, which also includes yellow
fever virus and Japanese encephalitis virus (2). Dengue virus
has four serotypes, DENV-1 to DENV-4. Infection with one of
these serotypes conveys life-long immunity but not cross-pro-
tective immunity to the other serotypes (2). Serologic analysis
is difficult because of cross-reactivity between the viruses.
However, together with clinical symptoms and travel history,
dengue serology can yield a diagnosis (3). Humans are infect-
ed with dengue virus by the bite of infective Aedes mosquitoes.
The most important vector is Aedes aegypti (1), which prefers
to feed on humans during daylight hours. The incubation time
is 3–14 days, most often 4–7 days (2).
DF is endemic in most countries in the tropical areas of
southern and Southeast Asia, the Western Pacific regions,
Central and South America, the Caribbean, and Africa (1,4).
Transmission of DF increases during the rainy season (1,5).
With an increased travel to tropical countries (6), and an
increased incidence of DF in these countries (1,7), DF has
become the most common imported arbovirus disease in
Sweden (8). In the absence of an effective vaccine, pretravel
advice, mainly on protection against mosquito bites, is impor-
tant to prevent the disease (2,7,9). Such advice should be
focused on individual risk assessments, based on available epi-
demiologic data. The aim of this study was, in the light of
changing travel patterns, to give an update on risk factors for
DF in order to form the basis for pretravel advice.
Patients and Methods
Cases
The Department of Virology at the Swedish Institute for
Infectious Diseases is the only laboratory in Sweden that per-
forms dengue serology. Indirect immunofluorescence is used
for the diagnosis. Antibody detection by indirect immunofluo-
rescence has proved to be at least as reliable as hemagglutina-
tion inhibition for diagnosis of DF in Swedish patients (3,10).
All cases with a positive dengue serologic test diagnosed at the
Swedish Institute for Infectious Diseases in 1998 and 1999
were considered for inclusion in the study. Thus, 114 patients,
92 from 1998 and 22 from 1999, were identified. Seven
patients were excluded from the study because of incorrect or
missing data that prevented us from confirming age and sex.
From the laboratory records, data for the remaining patients
were obtained on age, sex, name of physician, country of infec-
tion, and the date when the patient became ill. A detailed ques-
tionnaire on the journey, symptoms, preventive measures, and
pretravel advice was sent to the 107 case-patients through their
physicians. 
Control Group
A control population consisting of travelers to dengue-
endemic countries was used (Åre Marknadsfakta AB, Åre,
Sweden). The Åre dataset is a commercial database, based on a
randomized selection of 2,000 members of the Swedish popu-
lation every month. These persons are interviewed by tele-
phone with questions on recent overnight travel outside
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ber of Swedish travelers abroad. No data on any illness are
available from this dataset. The data are presented as journeys
per principal country or geographic area, categorized by age,
sex, length of journey, and purpose for travel (business or
leisure). A total of 4,217 persons with overnight travel abroad
were recorded in the Åre database for 1998 and 1999; 292 had
traveled to dengue-endemic countries or regions, defined as
those reporting one or more dengue cases to the World Health
Organization (WHO) in 1998 (11). These 292 persons were
included as controls. 
Statistics
Odds ratios (ORs) with the corresponding 95% confidence
interval (CI) were calculated as relative risk measures to assess
the risk factors for being diagnosed with DF. These ORs should
be interpreted as the odds of being exposed to a risk factor
among the cases divided by the odds of being exposed to that
risk factor among the controls, given that only traveling to
areas with risk of DF is under consideration. To study whether
risk factors were confounded, stratified analyses were per-
formed and Mantel-Haenszel ORs calculated. We performed all
analyses with Epi Info 6.04 software (Centers for Disease
Control and Prevention, Atlanta, GA).
Results
Cases
Most cases (95 of 107) were investigated at departments of
infectious diseases throughout Sweden. Of the original 107
patients who received a questionnaire, 74 (69%) responded. DF
was diagnosed in 59 responders and 29 nonresponders in 1998
and in 15 responders and 4 nonresponders in 1999. Of the 74
responders, 40 (54%) were women and 34 men, compared with
13 (39%) women and 20 men among the nonresponders
(p=0.16). The responders were of similar age (median 28 years;
range 19–60 years), as the nonresponders (median age 28
years; range 8–52 years). Age distribution did not differ
between the different countries of infection.
Country of Infection
The country where the person was staying 3–14 days before
becoming ill with DF was considered the country of infection.
Data on country of infection were available for 105 of the 107
patients. Most patients (75 of 105; 71%) were infected in
Thailand. The remaining patients were infected in 15 different
countries (Table 1). The DF risk per 1,000 travelers is shown in
Table 2, in comparison with the number of cases reported to
WHO in 1998 (11).
In the Figure, month of disease onset (combined for 1998
and 1999) is shown for the 75 travelers to Thailand. For com-
parison, the mean seasonal variation for indigenous cases in
Thailand in the years 1987–1991 (5) is also shown.
Length of Stay
The median length of time spent abroad for the 74 case-
patients was 30 days (range 11–496 days). The length of stay in
the country of infection was less in some cases, since one per-
son could have traveled to more than one country. The mean
length of stay did not differ between the different countries of
infection. 
Risk Factors for DF
With the Åre sample used as controls, ORs for a diagnosis
of DF were calculated for the risk factors of age, country of
infection, and length of stay (Table 3). Risk factors for DF were
travel to the Malay Peninsula (OR 4.95; 95% CI 2.92 to 8.46),
age 15–29 years (OR 3.03; CI 1.87 to 4.92), and travel duration
>25 days (OR 8.75; CI 4.79 to 16.06). OR for travel to the
Malay Peninsula was basically unchanged after stratification
by age group (OR 4.48) or length of stay (OR 4.41). When
stratified for travel versus no travel to the Malay Peninsula, the
results for length of stay remained unchanged, as did the results
for age group. The Åre database did not provide us with cross-
classified information about age group and length of stay so
those factors could not be studied together. Unadjusted ORs are
shown in Table 3.
Prophylaxis against Mosquito Bites
Bed nets as prophylaxis against mosquito bites were used
regularly by 17 of the DF patients, irregularly by 14 patients, and
never by 42 patients. Mosquito repellents were used regularly by
13 patients, irregularly by 37 patients, and never by 23 patients.
One person did not answer the questions on prophylaxis. 
Information on DF
Fourteen of 74 patients stated that they had been informed
about DF before the journey, 5 could not remember, and the
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Table 1. Country of infection for dengue fever cases  
Country of infection  All cases  Responders  Nonresponders 
Thailand  75  50  25 
Philippines  5  5  0 
India  4  3  1 
Caribbean Islands 
(unspecified)  4  3  1 
Malaysia  3  3  0 
Sri Lanka  2  2  0 
Central America 
(unspecified)  2  2  0 
Indonesia  2  0  2 
Nepal  1  1  0 
Singapore  1  1  0 
Cambodia  1  0  1 
Laos  1  1  0 
Vietnam  1  0  1 
Nicaragua  1  1  0 
Colombia  1  1  0 
Tanzania  1  1  0 
Unknown  2  0  2 
Total  107  74  33 
aDivided by responders and nonresponders to travel questionnaires. 
 remaining 55 patients stated they had not received any informa-
tion. Three of the 14 informed patients had received the infor-
mation from their doctor; the rest had received it from friends,
the Internet, or travel literature. Of the 74 patients, 23 were
aware that DF occurred at the country of infection. 
Clinical Data
Thirty patients visited a physician in the country where they
became ill, as well as after returning to Sweden. All patients
had fever, and 58 patients (78%) had headache. The other non-
hemorrhagic symptoms noted were retroorbital pain (n=23;
31%), musculoskeletal and joint pain (n=54; 73%), conjunc-
tivitis (n=17; 23%), rash (n=46; 62%), gastrointestinal com-
plaints (n=12; 16%), neurologic complaints (n=8; 11%), psy-
chologic complaints (n=3; 4%), alopecia (n=2; 3%), and respi-
ratory complaints (n=1; 1%). One or more hemorrhagic mani-
festations consistent with DHF (12) were observed in 21
patients, including petechiae (n=12; 16%), epistaxis (n=9;
12%), hematuria (n=2; 3%), hematemesis (n=2; 3%), melena
(n=2; 3%), menorrhagia (n=2; 3%), gum bleeding (n=2; 3%),
and internal bleeding (n=1; 1%). The one patient with internal
bleeding stated that he was treated for DHF at a hospital in
Bangkok. He had lived in Laos earlier in his life but had no
knowledge of previous DF.
Discussion
The number of Swedes and other westerners traveling to
DF-endemic areas has steadily increased. The patients in our
study only included those Swedish patients with DF who, after
returning from their travels, visited a physician in Sweden who
made a diagnosis on the basis of a positive dengue serologic
test. Questionnaires were sent out with the help of the patients’
physicians. Whether the questionnaires ever reached the nonre-
sponders is not known. Responders were mostly women, and
nonresponders were mostly men. Age and country of infection
were similar between the groups, except for in travelers to India
and its neighboring countries (Afghanistan, Bangladesh,
Bhutan, Nepal, Pakistan, and Sri Lanka) and to Central
America, where fewer cases occurred in nonresponders than in
responders. We do not think that these differences significantly
affect the results and conclusions from this study. Since not all
persons with symptoms visited a physician, or only did so
abroad, our case-patients probably represent a small fraction of
the Swedish travelers ill with DF in the 2 study years. In 1998,
DF was diagnosed in considerably more patients in Sweden (92
patients) than during the previous years, 1991–1997 (median
24; range 0–45) (8). Similarly, in 1998 more than twice as
many cases were reported to WHO than the average for the 3
preceding years. 
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Table 2. Geographic area of DF infection, Swedish travelers to these countries, DF risk, and number of cases and incidence of DF/DHF per 
100,000 inhabitants
a,b 
Geographic area of infection
c  Dengue patients 
Estimate of all 
Swedish travelers 
DF risk/100,000 
travelers 
DF/DHF cases reported to 
WHO in 1998 
DF/DHF incidence 
rate/100,000/y 
India with its neighboring countries
d  7  12,000  58  707  <1 
Malay Peninsula
e  79  264,000  30  158,901  180 
China  0  32,000  0  15  <1 
The rest of Asia, excluding Japan
f  3  33,000  9  181,847  130 
Australia and Pacific Islands
g  7  103,000  7  132,126  40 
Caribbean Islands  4  165,000  2  24,545  121 
Central America  3  55,000  5  67,403  49 
South America  1  54,000  2  641,299  217 
West Africa
h  0  16,000  0  No data  No data 
East Africa
i  1  17,000  6  No data  No data 
South Africa
j  0  38,000  0  No data  No data 
Total  105  789,000  13  1,203,831  37 
aDF, dengue fever; DHF, dengue hemorrhagic fever; WHO, World Health Organization.  
bAs reported to WHO. Data are combined figures for 1998 and 1999, except for information from the WHO report, which covers 1998 (11). The DF/DHF incidence calculations are 
based only on those countries in the regions reporting DF/DHF cases to WHO.  
cCategorized according to the Åre database. 
dIndia, Afghanistan, Bangladesh, Bhutan, Nepal, Pakistan, Sri Lanka. 
eMalaysia, Singapore, Thailand. 
fBrunei, Cambodia, Lao People’s Democratic Republic, Maldives, Myanmar (Burma), North Korea, South Korea, Taiwan, Viet Nam. 
gAustralia, Indonesia, New Zealand, Papua New Guinea, Philippines, and other Pacific islands. 
hBenin, Burkina Faso, Ivory Coast, The Gambias, Ghana, Guinea, Guinea-Bissau, Cape Verde, Liberia, Mali, Mauretania. 
iEthiopia, Kenya, Somalia, Tanzania. 
jAngola, Lesotho, Madagascar, Malawi, Mocambique, Namibia, South Africa, Zambia, Zimbabwe. 
 
Figure. Month of disease onset in 75 Swedish patients with dengue fever
or dengue hemorrhagic fever infected in Thailand, compared with the
mean number of indigenous cases in Thailand per year, 1987–1991 (11).For the diagnosis, we used antibody detection by indirect
immunofluorescence. As with other antibody assays, such as
the hemagglutination inhibition method, serologic cross-reac-
tions with other flaviviruses cannot be ruled out. However, in
addition to their positive serologic results, all patients had a his-
tory of signs and symptoms compatible with DF. 
The data presented in this study only represent Swedish
travelers. The travel patterns of persons from other western
countries may differ. However, since we have adjusted for age,
sex, and length of travel, and the risk estimates are related to
the number of Swedes traveling to different countries, the main
conclusions should also be valid for travelers from other coun-
tries to those areas for which we have enough power to detect
elevated risks.
No data on travel-related illnesses in the controls were
available from the Åre database. Therefore we cannot exclude
the possibility that the control group could have included per-
sons who actually had DF during their travel. However, all cal-
culations are based on the odds of DF’s being diagnosed in
Sweden after the traveler returned home, not on the odds of
becoming ill with DF (for which we do not have any data). If
we consider the small number of diagnosed cases and controls
in relation to the estimated total number of travelers (circa
1:2,000), any single person being included both as a patient and
as a control would be unlikely. 
Large discrepancies exist between the calculated risks for
the Swedish travelers to become ill with DF in different regions
and the incidence rates of cases reported to WHO. Several fac-
tors might explain these variations, including the small number
of Swedish DF patients, different sensitivity of the surveillance
and reporting systems in different countries, and the classifica-
tion of regions in the Åre database, which sometimes includes
both dengue-endemic and nonendemic countries in a region.
Some of the non–DH-endemic countries thus included do not
have many tourists (e.g., Afghanistan, North Korea, Liberia),
but the inclusion of non–DH-endemic countries such as South
Korea, New Zealand, Chile, Argentina, and Uruguay may have
diluted the denominator sufficiently to give falsely low ORs for
the rest of Asia, South America, and Australia and Pacific
Islands. Furthermore, DF is endemic in only limited areas of
China and Australia. The risk of contracting DF in the disease-
endemic parts of these countries is therefore substantially high-
er than reflected by the low ORs in this study.
The main risk factors for DF were travel to the Malay
Peninsula (mainly Thailand), age 15–29 years, and travel dura-
tion >25 days. The Åre database is based on a relatively small
sample of travelers from each country; the results for other sin-
gle-risk countries is therefore more uncertain.
In 1998, many countries in Asia had unusually high levels
of DF and DHF (13). That year, Thailand reported >126,000
cases of DF and DHF to WHO, compared with 99,000 cases in
1997, and 38,000 cases in 1996 (11). The DF epidemic in Asia
in 1998 has probably also affected the odds for our case-
patients’ being infected in these countries. The results might
have been different if the study had been performed in a
nonepidemic year. 
Most Swedish travelers to Thailand were infected during
May to August, with a peak in July, a pattern that agrees with
that of indigenous cases in Thailand in 1987 to 1991. The
Swedish cases also peaked in December and January, a finding
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Table 3. Odds ratios for diagnosis of dengue fever, calculated for possible risk factors 
Risk factor  Ratio in cases  Ratio in controls  Odds ratio  95% CI
a 
Geographic area         
India with neighbors   7/105  7/292  2.91  0.89 to 9.50 
Malay Peninsula   79/105  111/292  4.95  2.92 to 8.46 
China  0/105  17/292  0.00  0.00 to 0.65 
The rest of Asia  3/105  15/292  0.54  0.10 to 1.98 
Carribean  4/105  40/292  0.25  0.06 to 0.72 
Central America  3/105  17/292  0.48  0.11 to 1.77 
South America  1/105  21/292  0.12  0.00 to 0.79 
West Africa  0/105  6/292  0.00  0.00 to 2.60 
East Africa  1/105  4/292  0.69  0.01 to 7.11 
South Africa  0/105  11/292  0.00  0.00 to 1.09 
Australia and Pacific Islands  7/105  43/292  0.41  0.15 to 0.97 
Age groups (y)         
0–14  2/107  14/292  0.38  0.04 to 1.69 
15–29  58/107  82/292  3.03  1.87 to 4.92 
30–44  33/107  79/292  1.20  0.72 to 2.01 
>45  14/107  117/292  0.23  0.12 to 0.43 
Sex         
Male  54/107  154/292  0.91  0.57 to 1.46 
Length of travel (nights)         
0–10  0/74  68/292  0.00  0.00 to 0.17 
11–17  16/74  149/292  0.26  0.14 to 0.50 
18–24  13/74  31/292  1.79  0.83 to 3.82 
>25  45/74  44/292  8.75  4.79 to 16.06 
aCI, confidence interval. that does not agree with the indigenous Thai cases. Most like-
ly, this second peak among the Swedes reflects the travel pat-
tern of many tourists who traveled to Thailand during the
Christmas and New Year’s holiday. Asimilar two-peak season-
al pattern was also observed among Israeli DF patients return-
ing from Thailand in 1998 (14).
The general symptoms in the travelers with DF agreed with
symptoms previously described (1,2). Many patients had clini-
cal hemorrhagic manifestations, consistent with DHF (21/74).
WHO’s case definition for DHF includes thrombocytopenia as
well as plasma leakage. Since we did not have access to labo-
ratory test results, we cannot say how many of the patients ful-
filled WHO’s DHF case criteria. Patients with hemorrhagic
manifestations may be more inclined to seek medical care than
other DF patients, which would explain our findings.
In conclusion, DF is an important infection threatening trav-
elers to disease-endemic areas. In the absence of available vac-
cines, pretravel advice on mosquito protection is important
when attempting to reduce the number of DF cases in travelers.
Only 3 of 74 case-patients in our study had received pretravel
advice on DF from their doctor. Such advice should be given to
all travelers to DF-endemic areas, but young person traveleing
to southern and Southeast Asia for >3 weeks (31% of the
patients in our study) may be more likely to benefit by adhering
to it. This advice should also be given to travelers going to areas
where DF is endemic, even when the disease is not in season.
Dr. Lindbäck is a physician with a keen interest in epidemiology
and travel medicine. This analysis was conducted during her graduate
studies.
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